Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Enanta Pharmaceuticals EBITDA Margin % Related Terms
Enanta Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Enanta Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:9EP vs PBYI, IPSC, BNTC: EBITDA Margin % Comparison
For the Biotechnology subindustry, Enanta Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals (STU:9EP) has a EBITDA Margin % of -49.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enanta Pharmaceuticals and its competitors. According to the industry distribution chart, Enanta Pharmaceuticals ranks #470 out of 939 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Enanta Pharmaceuticals' EBITDA Margin % too high?
Enanta Pharmaceuticals' current EBITDA Margin % is -49.88%. Based on the distribution chart, Enanta Pharmaceuticals ranks #470 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' EBITDA Margin % compare to PBYI and IPSC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #470 out of 939 companies for EBITDA Margin %. This places Enanta Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current EBITDA Margin % is -49.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.57, compared to a current price of €11.50 — trading 51.9% above its estimated fair value. The current EBITDA Margin % is -49.88%. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current EBITDA Margin % is -49.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of €11.50 is trading 51.9% above its estimated GF Value™ of €7.57.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:9EP:
EBITDA Margin %: -49.88%
GF Value™: €7.57 vs. price of €11.50 (51.9% above fair value)
No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score
Get the complete analysis for STU:9EP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9EP has been successfully added to your 
